Standardisation of measurements of neurodegenerative disease biomarkers

神经退行性疾病影响了900多万欧洲人，给社会带来了巨大的经济负担。NDD生物标记物将疾病与病理过程联系起来，并帮助药物开发，从而改变了研究格局。NDD生物标志物通过使用非侵入性工具提高了诊断和预后的准确性。然而，由于缺乏标准化，它们在临床实践中的实施受到了阻碍。该项目将建立在以前EMPIR项目的基础上，以标准化生物标记物的测量，协调化验制造商之间的测量，建立质量评估方案，开发和实施新的生物标记物。

Neurodegenerative disorders (NDDs) affect over nine million Europeans and constitute a large economic burden to society. NDD biomarkers have transformed the research landscape by linking diseases to pathological processes and assisting drug development. NDD biomarkers improve the accuracy of diagnosis and prognosis with the use of non invasive tools. However, their implementation in clinical practice is hampered by a lack of standardisation. This project will build on previous EMPIR projects to standardise biomarker measurements, harmonise measurements across assay manufacturers, establish quality assessment programmes, develop and implement new biomarkers.